Open an account

Cellectar Biosciences

CLRB · NASDAQ

$1.23+$0.11 (+9.82%)TodayMarket closed ·
Prev close $1.12

About CLRB

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 11 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

Employees
11
Headquarters
Florham Park, New Jersey
Listed
May 20, 2005
Sector
Health Care
Industry
Biotechnology
Website
cellectar.com

CLRB key statistics

Market cap
10.59M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
165.11K
Volume
91.83K
Open price
$1.13
High today
$1.24
Low today
$1.12
52 Week high
$5.07
52 Week low
$1.12

Cellectar Biosciences (CLRB) at a glance

Cellectar Biosciences (CLRB) last traded at $1.23, with a market cap of 10.59M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.12 and $1.24. The current price is 9.8% above the day's low and 0.8% below its high.

Volume so far is 91.83K shares, below the average of 165.11K shares a day.

Over the past year Cellectar Biosciences has ranged from $1.12 to $5.07, and now sits 3% of the way up that range.

Cellectar Biosciences met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.57 per share against an estimate of -$0.493.

The average analyst price target is $11.73, 853.7% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $11.73
Low
$10.10
Now
$1.23
High
$15.75

CLRB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 39.4% on average.

  1. Q3 FY24: reported -$12.00 per share against an estimate of -$11.40
  2. Q4 FY24: reported -$1.80 per share against an estimate of -$10.79
  3. Q1 FY25: reported -$4.20 per share against an estimate of -$5.00
  4. Q2 FY25: reported -$3.39 per share against an estimate of -$3.98
  5. Q3 FY25: reported -$1.41 per share against an estimate of -$2.58
  6. Q4 FY25: reported -$1.29 per share against an estimate of -$2.34
  7. Q1 FY26: reported -$1.30 per share against an estimate of -$1.92
  8. Q2 FY26: reported -$0.57 per share against an estimate of -$0.493

CLRB news

  • Press releaseGlobe Newswire

    Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia

  • Press releaseGlobe Newswire

    Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia

  • Press releaseGlobe Newswire

    Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

  • Press releaseGlobe Newswire

    Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

  • Press releaseGlobe Newswire

    Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

  • Press releaseGlobe Newswire

    Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

  • Vandana Singh

    What's Going With Cellectar Biosciences Stock On Wednesday?

  • Avi Kapoor

    Crude Oil Down 4%; PayPal Shares Fall After Q1 Results

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.